Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269200 · ClinicalTrials.gov registry record · Phase 3
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A Phase 3 study of Endometrial Neoplasms, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 805
- Enrollment target
- 20
- Study locations
NCT04269200: Active Phase 3 study of Endometrial Neoplasms, sponsored by AstraZeneca.
NCT04269200 is a Phase 3 study of Endometrial Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 805 participants, above the 319-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (152% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269200, a Phase 3 study of Endometrial Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 805 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Primary Outcome
To demonstrate the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 \[RECIST 1.1\]) in patients with newly diagnosed advanced or recurrent endometrial cancer
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG olaparib
- BIOLOGICAL durvalumab
- DRUG durvalumab placebo
- DRUG olaparib placebo
Study Locations (20)
California
- Research Site - Concord
- Research Site - La Jolla
- Research Site - San Francisco
- Research Site - Santa Barbara
Florida
- Research Site - Fort Lauderdale
- Research Site - Tampa
Illinois
- Research Site - Arlington Heights
- Research Site - Chicago
Arizona
- Research Site - Tucson
Colorado
- Research Site - Aurora
Georgia
- Research Site - Savannah
Hawaii
- Research Site - Honolulu
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 805 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2027-04-01 |
| Phase | Phase 3 |
What the registry record for NCT04269200 still lists
NCT04269200 is an interventional study that assigns participants to a tested intervention. The registered 805 participants enrollment target is mid-sized for trials with a published cap, above the 319-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (152% higher).
The record links to 1 condition, with Endometrial Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04269200 names 20 study sites across 15 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04269200 about?
NCT04269200 is a clinical study titled "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer". A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
What is the current status of trial NCT04269200?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 805 participants. The study started on 2020-05-05. Estimated completion is 2027-04-01.
What conditions does trial NCT04269200 study?
This clinical trial studies the following conditions: Endometrial Neoplasms.
What interventions are being tested in trial NCT04269200?
The interventions under investigation include: Carboplatin (DRUG), olaparib (DRUG), durvalumab (BIOLOGICAL), durvalumab placebo (DRUG), olaparib placebo (DRUG).
Who is sponsoring clinical trial NCT04269200?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04269200 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04269200's enrollment target sits among peer trials
805 2nd of 14 the highest of 14 other Endometrial Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI